Following U.S. Food and Drug Administration review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal [...]
Filed under: News Wire | Tagged: Clinical Trials, Oncolytics Biotech, phase 2 | Leave a Comment »
